Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
Adult
Aged
BRCA1 Protein
/ genetics
BRCA2 Protein
/ genetics
Breast Neoplasms
/ genetics
Female
Humans
Italy
Middle Aged
Mutation
Ovarian Neoplasms
/ genetics
Ovariectomy
/ adverse effects
Personal Satisfaction
Prophylactic Surgical Procedures
/ adverse effects
Prospective Studies
Risk Reduction Behavior
Salpingectomy
/ methods
Salpingo-oophorectomy
/ adverse effects
Treatment Outcome
Journal
Menopause (New York, N.Y.)
ISSN: 1530-0374
Titre abrégé: Menopause
Pays: United States
ID NLM: 9433353
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
pubmed:
4
2
2021
medline:
20
3
2021
entrez:
3
2
2021
Statut:
epublish
Résumé
BRCA carriers are recommended to undergo prophylactic risk-reducing salpingo-oophorectomy (RRSO). Possible adverse health impacts of RRSO, particularly when done before natural menopause, can reduce the long-term satisfaction with this risk-reducing strategy. The aim of this study was to prospectively evaluate the level of satisfaction of women undergoing RRSO, also in relation to some specific characteristics at RRSO. A prospective cohort study was performed in the Modena Family Cancer Clinic of the University Hospital of Modena (Italy). All BRCA1/2 confirmed mutation carriers who decided to undergo RRSO were recruited between 2016 and 2019. Fifty-five women (29 BRCA1 and 26 BRCA2) (mean age: 50.4 ± 7.7 years [range 35-79]) were included with a mean follow-up after RRSO of 660.9 days (1.8 years) (range 35-1,688 days) (median: 549 days). No intraepithelial (Serous Tubal Intraepithelial Carcinoma)/invasive cancers were found (0%) at RRSO. No vasomotor symptoms at 1 month after surgery were reported by 11/22 (50%) premenopausal women at RRSO. All women (100%) with new "RRSO-caused" vasomotor symptoms with no previous breast cancer initiated postmenopausal hormone therapy. At the final follow-up the satisfaction rate (0-100 visual analog scale points) of the participants was 96.4 ± 8.6 points (range 62-100). To the question "Would you undergo RRSO again if it was proposed today? (0-100 visual analog scale points)" the answer was 99.4 ± 3.2 points (range 79-100). These scores were in general very high and did not change in the different groups according to pre/postmenopausal status at RRSO, cancer survivors versus healthy women at RRSO, BRCA status, hormone therapy users/nonusers after RRSO, "RRSO-caused" symptoms versus not RRSO-caused (P > 0.05). Findings from this prospective study suggest that satisfaction with RRSO is very high and little dependent on the participants' characteristics at surgery. Women at high risk for ovarian cancer are very satisfied with their choice of risk-reduction strategy. Video Summary:http://links.lww.com/MENO/A712.
Autres résumés
Type: plain-language-summary
(eng)
Video Summary:http://links.lww.com/MENO/A712.
Identifiants
pubmed: 33534430
doi: 10.1097/GME.0000000000001737
pii: 00042192-202103000-00006
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
263-270Informations de copyright
Copyright © 2021 by The North American Menopause Society.
Déclaration de conflit d'intérêts
Financial disclosure/conflicts of interest: A.T. has received funding from Eli Lilly and Roche. F.F. has received funding from Loli Pharma International and Zambongroup SRL. The other authors have nothing to disclose.
Références
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317:2402–2416.
Toss A, Molinaro E, Sammarini M, et al. Hereditary ovarian cancers: state of the art. Minerva Med 2019; 110:301–319.
Cortesi L, De Matteis E, Toss A, et al. Evaluation of transvaginal ultrasound plus CA-125 measurement and prophylactic salpingo-oophorectomy in women at different risk levels of ovarian cancer: the Modena Study Group Cohort Study. Oncology 2017; 93:377–386.
Grandi G, Del Savio MC, Sammarini M, et al. The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: a prospective cohort, other biomarker controlled, study. Eur J Cancer Prev 2020; 29:350–356.
National Comprehensive Cancer Network (NCCN) Guidelines, Hereditary Breast and/or Ovarian Cancer, 2019. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx#detection. Accessed November 5, 2020.
Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 2002; 38: (suppl. 6): S15–S17.
Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346:1609–1615.
Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006; 296:185–192.
Grandi G, Perrone AM, Perrone A, et al. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy? Maturitas 2021; 143:59–64.
Xiao YL, Wang K, Liu Q, et al. Risk reduction and survival benefit of risk- reducing salpingo- oophorectomy in hereditary breast cancer: meta-analysis and systematic review. Clin Breast Cancer 2019; 19:48–65.
Mai PL, Miller A, Gail MH, et al. Risk-reducing salpingo-oophorectomy and breast cancer risk reduction in the gynecologic oncology group protocol-0199 (GOG-0199). JNCI Cancer Spectr 2019; 4:kz075.
Kotsopoulos J, Huzarski T, Gronwald J, et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2016; 109:djw177.
Kaunitz AM, Faubion S. Surgical menopause: health implications and hormonal management. Menopause 2020; 28:1–3.
Finch A, Narod SA. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review. Maturitas 2011; 70:261–265.
Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004; 22:1045–1054.
Grandi G, Caroli M, Cortesi L, Toss A, Tazzioli G, Facchinetti F. Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which? Expert Opin Drug Saf 2020; 19:1025–1030.
Westin SN, Sun CC, Lu KH, et al. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer 2011; 117:2659–2667.
Hooker GW, King L, Vanhusen L, et al. Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers. Hered Cancer Clin Pract 2014; 12:9.
Swisher EM, Babb S, Whelan A, Mutch DG, Rader JS. Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction. J Reprod Med 2001; 46:87–94.
Greene JG. A factor analytic study of climacteric symptoms. J Psychosom Res 1976; 20:425–430.
Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev 2018; 4:CD002748.
Frost MH, Schaid DJ, Sellers TA, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 2000; 284:319–324.
Hall E, Finch A, Jacobson M, et al. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol 2019; 152:145–150.
Vermeulen RFM, Beurden MV, Korse CM, Kenter GG. Impact of risk-reducing salpingo-oophorectomy in premenopausal women. Climacteric 2017; 20:212–221.
Robson M, Hensley M, Barakat R, et al. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 2003; 89:281–287.
Chan JL, Senapati S, Johnson LNC, et al. Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingooophorectomy. Menopause 2019; 26:132–213.
Tucker PE, Cohen PA. Review article: sexuality and risk-reducing salpingo-oophorectomy. Int J Gynecol Cancer 2017; 27:847–852.
Finch A, Metcalfe KA, Chiang JK, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 2011; 121:163–168.
Powell CB, Alabaster A, Le A, Stoller N, Armstrong MA, Raine-Bennett T. Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations. Psychooncology 2020; 29:331–338.
Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab 2017; 102:3647–3661.